Blog

Artificial Intelligence in Healthcare, AI Health, digital healthcare provider, telemedicine, medical technology

IBM Watson Health was once the "poster child" for artificial intelligence in medicine. After winning Jeopardy! in 2011, IBM pivoted its supercomputer toward the "moonshot" goal of curing cancer.However, by 2022, IBM sold off the remains of Watson Health to a private equity firm for a fraction of its investment.The failure wasn't due to one single bug, but rather a perfect storm of technical limitations, "black box" secrecy, and a fundamental misunderstanding of how doctors actually work.&nbsp;1. The Data "Bias" ProblemThe crown jewel of the initiative was Watson for Oncology. To train it, IBM partnered with the Memorial Sloan Kettering Cancer Center (MSK).Hypothetical vs. Real World: Instead of learning from millions of diverse patient outcomes, Watson was largely trained on "synthetic" or hypothetical cases created by a small group of MSK doctors.&nbsp;The Result: The AI didn't provide "universal" medical wisdom; it provided "The MSK Way." When doctors in Denmark or India used Watson, they found it recommended drugs they didn't have access to or treatments that ignored their local medical guidelines.&nbsp;2. Technical Limitations (The "Black Box") IBM marketed Watson as a machine that could "understand" medical literature. In reality, Watson struggled with the messy nature of healthcare data.Unstructured Data: Doctors’ notes are full of jargon, shorthand, and nuances. Watson often failed to parse this "unstructured" text correctly, leading to incorrect summaries.Lack of Explainability: Medicine is built on evidence. When Watson made a recommendation, it often couldn't explain why. Doctors, who are legally and ethically responsible for their patients, were unwilling to trust a "black box" that might suggest an unsafe treatment without a clear rationale.3. The "Hype" GapIBM’s marketing department was years ahead of its engineering department.The Promise: TV commercials suggested Watson could look at a patient and instantly find a cure that human doctors missed. The Reality: In many trials, Watson simply confirmed what doctors already knew, but at a much higher cost and with a slower interface. It wasn't a "super-doctor"; it was an expensive digital filing cabinet that occasionally gave bad advice. 4. Operational Friction Hospitals are high-stress environments where every second counts.Workflow Disruption: Using Watson required doctors to manually input massive amounts of data into a new, separate system. For overworked oncologists, the "benefit" of the AI didn't outweigh the "cost" of the time spent feeding it data. High Costs: Implementing Watson cost some hospitals tens of millions of dollars. When the "Moonshot" failed to deliver immediate ROI or better patient outcomes, major partners like MD Anderson cancelled their contracts.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

IBM Watson was once heralded as the Future of Healthcare AI: What exactly went wrong?

Exec Summary:The combination of technological advancements, regulatory changes, market dynamics, and increased investor interest is driving healthtech M&amp;A valuations to new heights. Companies with innovative technologies, strong market positions, and the potential to address significant healthcare challenges are likely to be highly valued in today's M&amp;A market.In terms of valuation, the 10 Key Variables in HealthTech and MedTech M&amp;A valuation multiples in Q1 2026 are:1) Stage of the company's development: Early-stage companies are typically valued at a lower multiple than more mature companies.2) Size of the company: Larger companies are typically valued at a higher multiple than smaller companies.3) Intellectual property portfolio: Companies with valuable intellectual property are typically valued at a higher multiple.4) Quality of the management team: A strong management team can add value to a company and may lead to a higher valuation.5) Revenue growth: This is one of the most important factors in determining the valuation of a healthtech company. Companies with strong revenue growth are typically valued at a premium to those with slower growth.6) Gross margin: Gross margin is a measure of a company's profitability. Companies with higher gross margins are typically valued at a premium to those with lower margins.7) Customer acquisition costs: Customer acquisition costs (CAC) are the costs associated with acquiring new customers. Companies with lower CACs are typically valued at a premium to those with higher CACs.8) Market share: Market share is a measure of a company's dominance in its industry. Companies with a large market share are typically valued at a premium to those with a smaller market share.9) Regulatory landscape: The regulatory landscape for healthtech is constantly evolving. Companies that operate in industries with a favourable regulatory environment are typically valued at a premium to those that operate in industries with a more challenging regulatory environment.10) Technology moat: A technology moat is a competitive advantage that makes it difficult for other companies to compete with a company. Companies with a strong technology moat are typically valued at a premium to those that do not have a moat.Contact us to discuss how Nelson Advisors can help your HealthTech business. <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

10 Key Variables driving HealthTech M&A valuation multiples in 2026

Nelson Advisors thought leadership blog Healthcare.Digital has been referenced in Forbes Argentina's 'Women's health: 27 mega-deals and a record market of US$ 100 billion' articleSalud femenina: 27 mega-acuerdos y un mercado récord de US$ 100.000 millonesSegún Silicon Valley Bank, las fusiones y adquisiciones se convirtieron en la estrategia de salida predominante en el sector salud. Esto ocurre porque los mercados públicos siguen siendo difíciles de alcanzar y escalar para las startups: las ventanas para ofertas públicas de venta son restrictivas para la mayoría, y el capital privado terminó siendo el camino más accesible para concretar salidas.Source: <a href="https://www.forbesargentina.com/negocios/salud-femenina-27-mega-acuerdos-mercado-record-us-100000-millones-n85020">https://www.forbesargentina.com/negocios/salud-femenina-27-mega-acuerdos-mercado-record-us-100000-millones-n85020</a>

Nelson Advisors referenced in Forbes Argentina article

Nelson Advisors featured in Silicon Republic's "Medtech in 2026 to be shaped by innovation and compliance' articleInnovation Versus Resilience: The False Trade-OffBoth the Deloitte survey and Nelson Advisors’ IPO predictions emphasize resilience as organizations navigate uncertainty. But resilience isn’t achieved through caution—it’s built through practice.As companies grow larger, they tend to become more risk-averse. They reward not taking risks, which atrophies the resilience muscle. In product development, I consistently see larger organizations being too conservative. Some fraction of every budget must fund the innovation side of the business, or you become obsolete.This is where the IPO market dynamics become fascinating. Nelson Advisors predicts 2026 will mark “The Return of the Mega-Deal,” with large healthcare IPOs like Zelis Healthcare (projected at $1B+ valuation) and potential Medtronic MiniMed spin-offs entering the market. Companies demonstrating measurable AI ROI are particularly attractive.But here’s the challenge: after an IPO, public scrutiny intensifies dramatically. I’ve been in startups that went public, then bought themselves back private—twice—because managing investors while managing the business proved nearly impossible.Amazon cracked this code by telling investors upfront: “We’re going to waste this big chunk of change every year trying innovative things.” As long as they manage both the business and the narrative, it works. In medtech, I haven’t seen anyone successfully balance both. Most bigger companies avoid any scent of risk, which tamps innovation down and they just repeat what worked last year and wonder why their performance is lagging that of their “worthy rivals”.The Competitive Divide Is WideningCompanies not using AI in their development processes and daily operations will be bypassed by startups and competitors who do. This isn’t hypothetical. I’m watching it happen in real-time.In 2025 alone, we’ve moved from chaotic AI experimentation to sophisticated automation using tools like Claude Code. The teams I work with in my biweekly executive roundtable are experiencing radical capability increases with the same headcount and hours in the day.The startups entering the IPO pipeline understand this. According to Nelson Advisors’ watchlist, companies like Sword Health (digital MSK care, $4B valuation) and Maven Clinic (women’s and family health, $1.7B valuation) are positioning for liquidity events precisely because they’ve integrated AI into their operational DNA.Meanwhile, established companies debate whether AI is worth the investment.Source: <a href="https://med-tech.world/news/healthcare-2026-why-resilience-trumps-caution-in-the-ai-era/">https://med-tech.world/news/healthcare-2026-why-resilience-trumps-caution-in-the-ai-era/</a>

Nelson Advisors featured in MedTech World's 'Healthcare 2026: Why resilience trumps caution in the AI era'  article

European HealthTech this week is dominated by regulatory fine‑tuning around AI in devices, fresh EU‑level funding calls, and continued capital and grant focus on AI‑enabled care delivery and data platforms.Regulation and policyThe Commission is positioning the European Health Data Space as a backbone to enable trustworthy AI in healthcare, with a push to turn AI Act and EHDS texts into live deployment projects at the bedside.​A Commission working paper highlights four flagship AI-in-health initiatives, including EU AI‑powered screening centres and a network of AI deployment expertise, plus actions to speed market entry of medical devices without compromising safety.​In parallel, a proposed tweak to the AI Act would move MDR/IVDR from Annex I Section A to B, reducing overlap so most AI-enabled medical devices remain high‑risk but are largely governed through MDR/IVDR rather than dual regimes.EU and national funding windowsHorizon Europe’s 2026–2027 Health Cluster work programme is now live at info‑day level, signalling sizeable calls (often 1.5–10 million euros per project) for digital health, AI, and data‑intensive health R&amp;I from February 2026.Innovative Health Initiative Call 12 is open, targeting large AI‑driven decision support, mobile health, remote monitoring, interoperability and evaluation projects, with a 21 April 2026 deadline and encouragement of big cross‑sector consortia.Recent healthtech commentary notes this funding stack alongside Horizon and other schemes as a key driver of European digital health platforms, particularly those built around real‑world deployment and system‑level impact.Market and strategic themesSector analysis this month underlines that capital is available but is flowing selectively into data‑rich platforms, cross‑border models and AI‑enabled diagnostics that can navigate the AI Act / MDR / HTA regime.Legal and policy advisers in Europe flag 2026–2027 as a crunch period for AI-in-health compliance, with only about 1.5 years left before high‑risk AI obligations in healthcare fully bite, pushing vendors to harden documentation, governance and post‑market monitoring.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>&gt;&gt;&gt;European MedTech this week is being shaped by MDR/IVDR simplification moves, the hardening EUDAMED timetable, and EU‑level initiatives (including the Biotech Act and IHI Call 12) that favour data‑rich, AI‑enabled devices.MDR/IVDR and EUDAMEDThe Commission’s MDR/IVDR simplification proposal (December 2025) is now being digested, with law‑firm analyses flagging 2026 as the year when portfolio rationalisation and “clean MDR roadmaps” become central to MedTech strategy and M&amp;A.EUDAMED’s staged rollout has formally triggered transition periods, with full use becoming mandatory by May 2027 and four core modules (actor registration, UDI/device data, notified bodies &amp; certificates, market surveillance) already live, making registration and transparency non‑negotiable for EU device launches.EU Biotech Act and AI-enabled devicesThe new EU Biotech Act package explicitly links AI and data with medical device and biotech innovation, tasking EMA and the Commission with guidance and “AI‑first” coordination across health technologies.A key Digital Omnibus proposal would move MDR/IVDR from Section A to Section B of Annex I of the AI Act, meaning most AI‑enabled medical devices would primarily comply via MDR/IVDR, easing duplicative AI Act burdens while keeping them high‑risk and tightly supervised.Funding and strategic signalsIHI Call 12 has opened with large, single‑stage topics including digitalisation and data exchange in healthcare, creating consortium‑style funding opportunities for diagnostics, monitoring, and integrated device‑plus‑data solutions.Recent European commentary expects M&amp;A and growth capital in MedTech to concentrate on fewer, higher‑quality assets that pair robust MDR/EUDAMED positioning with strong clinical‑economic evidence and AI/data moats, especially in robotics, neuro, advanced diagnostics, and workflow automation.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk﻿</a> &nbsp; &nbsp; &nbsp; &nbsp;

This Week in European MedTech and HealthTech: 30th January 2026

Healthcare AI at Lightspeed is framed as augmenting clinicians, not replacing them, by filling structural gaps in access and capacity.Core messageLightspeed explicitly argues that AI is not taking jobs from doctors but extending care teams to cover work they cannot reach, especially in primary care and mental health.​The thesis is that healthcare has a chronic shortage of clinicians, so AI’s role is to restore capacity, reduce bottlenecks, and handle lower‑value or administrative tasks.How AI “fills gaps” rather than displacesAI tools are positioned to offload documentation, routing, triage, and routine communication so doctors and nurses can focus on complex decision‑making and patient relationships.Lightspeed’s portfolio emphasis (e.g., scribing, RCM, front‑office automation, AI-augmented services like Gyde) reflects a bet on human‑in‑the‑loop systems that complement clinical judgment rather than automate it away.10 Key Points from Lightspeed's Healthtech January 2026 Newsletter&nbsp;Lightspeed sees healthcare as one of the fastest sectors for real-world AI adoption, with deployed systems already improving access, speed, and scalability of care delivery.​ The firm is actively pursuing an “AI roll‑up” strategy in healthcare services, where M&amp;A and AI are combined to modernize existing distribution and services businesses rather than only backing net-new startups. Gyde is highlighted as the first “AI-native” health brokerage platform, built to empower top brokers across insurance, wealth, and health decisions using a proprietary AI system plus experienced operating teams. Gyde’s model is acquisition-led: it partners with high-quality health insurance agencies (Medicare Advantage, employer benefits, individual markets), keeps local teams in place, and then scales them with a shared AI platform. The platform centers on GydeOS (broker-facing system) and Gia (an intelligent assistant) to automate low-complexity tasks such as data entry and routine follow-ups, freeing brokers to focus on complex advisory work and relationships. Lightspeed frames Gyde’s opportunity as solving a structurally underserved broker market, where brokers are central to critical consumer choices but constrained by fragmented, outdated tooling. On the infrastructure layer, Lightspeed has “tripled down” on Anthropic: after leading its Series E, it co-led a roughly 13 billion dollar Series F, cementing Anthropic as a core AI partner for health and life sciences. Anthropic is now explicitly targeting healthcare with Claude for Life Sciences and Claude for Healthcare, positioning frontier models as horizontal infrastructure for biopharma, providers, and payers. Lightspeed closed over 9 billion dollars in new funds in 2025 and is channeling a material portion into healthcare AI, with five stated vectors/themes it is investing behind in 2026 (including clinical AI “access” plays and services roll‑ups like Gyde).​ The overarching thesis is that AI in health is shifting from experiments to scaled operations: AI-enhanced brokerages, clinical tools, and infra (Anthropic/Claude) are presented as early exemplars of what “AI abundance” will look like for patients and the broader health system.Source: <a href="https://newsletter.lsvp.com/p/lightspeed-healthtech-january-newsletter" data-mce-href="https://newsletter.lsvp.com/p/lightspeed-healthtech-january-newsletter">https://newsletter.lsvp.com/p/lightspeed-healthtech-january-newsletter</a>For over twenty years Lightspeed Ventures has been the first investor and an early backer of some of the most innovative companies in the world. In service of bold founders with big ideas, we stand behind our companies with high conviction from Seed to Series F and beyond.<a href="https://lsvp.com/about/">https://lsvp.com/about/</a>

Nelson Advisors

Blog

IBM Watson was once heralded as the Future of Healthcare ...

10 Key Variables driving HealthTech M&A valuation multipl...

Nelson Advisors referenced in Forbes Argentina article

Nelson Advisors featured in MedTech World's 'Healthcare 2...

This Week in European MedTech and HealthTech: 30th Januar...

Lightspeed Venture Partners: Healthcare AI isn't displaci...